KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II...
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
About this item
Full title
Author / Creator
Luke, Jason J , Ascierto, Paolo A , Carlino, Matteo S , Gershenwald, Jeffrey E , Grob, Jean-Jacques , Hauschild, Axel , Kirkwood, John M , Long, Georgina V , Mohr, Peter , Robert, Caroline , Ross, Merrick , Scolyer, Richard A , Yoon, Charles H , Poklepovic, Andrew , Rutkowski, Piotr , Anderson, James R , Ahsan, Sama , Ibrahim, Nageatte and M Eggermont, Alexander M
Publisher
England: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Patients with high-risk stage II melanoma are at significant risk for recurrence after surgical resection. Adjuvant treatment options to lower the risk for distant metastases are limited. Although adjuvant IFN-α2b is associated with improved relapse-free survival in patients with high-risk melanoma, toxicity and limited overall survival benefits li...
Alternative Titles
Full title
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
Authors, Artists and Contributors
Author / Creator
Ascierto, Paolo A
Carlino, Matteo S
Gershenwald, Jeffrey E
Grob, Jean-Jacques
Hauschild, Axel
Kirkwood, John M
Long, Georgina V
Mohr, Peter
Robert, Caroline
Ross, Merrick
Scolyer, Richard A
Yoon, Charles H
Poklepovic, Andrew
Rutkowski, Piotr
Anderson, James R
Ahsan, Sama
Ibrahim, Nageatte
M Eggermont, Alexander M
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2330330270
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2330330270
Other Identifiers
ISSN
1479-6694
E-ISSN
1744-8301
DOI
10.2217/fon-2019-0666
